Healthtalk.com Hosts Free Patient Webcast on Multiple Sclerosis and the FDA's Reapproval of Tysabri June 22nd, 8:30 PM (Eastern)
Program to Feature Prominent MS Experts Discussing the Drug and What It Means for Consumers
    SEATTLE, June 15 /PRNewswire/ --
     WHAT:     HealthTalk Inc., a pioneer in patient education delivering live
               and web-based programs on the latest treatments and research
               news, is hosting a live webcast for Multiple Sclerosis
               patients, their families and caregivers.  Experts will be
               discussing the recall and the re-approval of the drug Tysabri
               as well as its benefits, safety and risk management.
               Consumers can participate via the live webcast or by phone.
     WHY:      There are more than 400,000 people who have been          diagnosed with
               Multiple Sclerosis in the U.S.  The drug Tysabri has recently
               been approved by the FDA for re-release for use in patients
               with relapsing forms of MS.
     WHO:      Howard Rossman, D.O., F.A.C.N.  Dr. Rossman spearheaded the
               creation of the M.I.N.D. Multiple Sclerosis Center located in
               Farmingham Hills, MI and serves as Medical Director of the
               Center which presently services over 1,800 patients with MS.
     WHEN:     Thursday, June 22nd 2006
               8:30 PM (Eastern)
               5:30 PM (Pacific)
     WHERE:    Register online at http://www.healthtalk.com/msprogram or
               call 1-800-522-3254.
     COST:     Free
    Press Contact:
    Alyssa Schaier, 914-589-6904
    aschaier@informedmedical.com
			
			
									
						
							Tysabri Free Webcast
A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis
			Return to “Tysabri (Antegren, Natalizumab)”
			
				Jump to
				
			
		
			
			
	
	- Multiple Sclerosis
 - ↳ General Discussion
 - ↳ Introductions
 - ↳ Drug Pipeline
 - ↳ Regimens
 - ↳ Undiagnosed
 - ↳ MS Etiology and Pathogenesis
 - Treatments
 - ↳ Chronic Cerebrospinal Venous Insufficiency (CCSVI)
 - ↳ Low Dose Naltrexone
 - ↳ Tysabri (Antegren, Natalizumab)
 - ↳ Copaxone
 - ↳ Glatopa
 - ↳ Avonex
 - ↳ Rebif
 - ↳ Betaseron
 - ↳ Plegridy
 - ↳ Novantrone
 - ↳ Aimspro
 - ↳ Diet
 - ↳ Stem Cells
 - ↳ Antibiotics
 - ↳ Campath (Lemtrada, Alemtuzumab)
 - ↳ Gene Therapy
 - ↳ Natural Approach
 - ↳ Biotin (Qizenday, Cerenday, MD1003)
 - ↳ Coimbra High-Dose Vitamin D Protocol
 - ↳ Statins
 - ↳ Tcelna (Tovaxin)
 - ↳ Revimmune (Cyclophosphamide, Cytoxan)
 - ↳ Medical Devices
 - ↳ Rituxan (Rituximab)
 - ↳ Ocrevus (Ocrelizumab)
 - ↳ Kesimpta (Ofatumumab)
 - ↳ Briumvi (Ublituximab-xiiy)
 - ↳ General Medications
 - ↳ Tecfidera (BG-12, Dimethyl fumarate)
 - ↳ Vumerity (Diroximel fumarate)
 - ↳ Bafiertam (Monomethyl fumarate)
 - ↳ Gilenya
 - ↳ Aubagio (Teriflunomide)
 - ↳ Mayzent (Siponimod)
 - ↳ Zeposia (Ozanimod)
 - ↳ Ponvory (Ponesimod)
 - ↳ Mavenclad (Cladribine)
 - ↳ Ampyra (Dalfampridine)
 - ↳ Medical Marijuana
 - ↳ Sativex
 - ↳ Chiropractic Treatment
 - Life
 - ↳ Daily Life
 - ↳ Veterans and MS
 - ↳ Trigeminal Neuralgia in MS
 - ↳ Reading Nook
 - ↳ Humor
 - ↳ Shopping
 - ↳ Friends and Family
 - ↳ Mental & Spiritual Health
 - ↳ Exercise and Physical Therapy
 - ↳ Under 25 with MS
 - ↳ MS in the Golden Years
 - ↳ Parenting Kids With MS
 - ↳ Parents with MS
 - ThisIsMS.com
 - ↳ Site Support
 - ↳ Suggestions